(Date:11/6/2009)...v. 6 ,, 3Q09 Corpo...tenza(TM) E.U. Marketing Authorization to Astellas... commercial readiness activities Expanded managem...keting; and Director, Commercial Operations Appoi...Audit Committee chairman , Upcoming 2009 Mi...
(Date:11/6/2009)... 6 Intarcia Therapeutics, Inc. del...ROS® continuous delivery of exenatide) progra...h Annual Diabetes Technology Meeting in San Franci...bin/prnh/20050301/SFTU126LOGO ) ,, Continuous...owers Plasma Glucose, HbA1c and Reduces Weight in ...
(Date:11/5/2009)...v. 5 GenVec, Inc. (Nasda...or the third quarter ended September 30, 2009. Gen... share) for the three months ended September 30, 2...per share) in the comparable quarter of 2008. For ... net loss was $14.1 million ($0.15 per share), com...
(Date:11/5/2009)...Newswire-FirstCall/ -- Imagenetix, Inc. (OTC Bulle...ncer, President and CEO of Imagenetix, will be pre...ICRO Conference on Thursday, December 3rd, at 10:3...About LD MICRO ,, LD MICRO is a by-invitation o...alued companies in the micro-cap space. Since 2002...
Breaking Biology Technology:NeurogesX Reports Third Quarter 2009 Results 2NeurogesX Reports Third Quarter 2009 Results 3NeurogesX Reports Third Quarter 2009 Results 4NeurogesX Reports Third Quarter 2009 Results 5NeurogesX Reports Third Quarter 2009 Results 6NeurogesX Reports Third Quarter 2009 Results 7NeurogesX Reports Third Quarter 2009 Results 8NeurogesX Reports Third Quarter 2009 Results 9NeurogesX Reports Third Quarter 2009 Results 10Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 2Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 3Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 4Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 5GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6Imagenetix to Present at 2nd Annual LD MICRO Conference at the Luxe Sunset Bel Air 2... , When: Tuesday, April 22 ... Networking Reception 5:30 p....30 p.m., Where: 610 Hilton Blvd., A...courtaa.com/ann_arbor_city_map_directions.html ), ...ranslation Industry experts ...
...ewswire-FirstCall/ - Victhom Human Bionics,Inc. (V...from the ongoing,human clinical trial of its Close...urostep(TM) for the treatment of patients sufferin...stem lesion. According to the Company, the,initial...eurostep(TM) is,capable of collecting sensory sign...
... 16 /PRNewswire-FirstCall/ - Anavex Life,Sciences ... appointment of,Dr. Dimitri Goundis as Project Dir...res to enter human clinical trials with its lead A...r. Goundis has more than 20 years experience in th...hip positions at Speedel AG (SWX: SPPN),The Medici...
Other Biology Technology:MichBio Will Host Workshop on Capital Formation Prior to April 22 Annual Meeting 2Victhom announces promising results on the proof of concept for its unique closed-loop neuromodulation system 2Anavex appoints Dr. Dimitri Goundis to lead Clinical Development 2Anavex appoints Dr. Dimitri Goundis to lead Clinical Development 3Anavex appoints Dr. Dimitri Goundis to lead Clinical Development 4BD BaculoGoldTM Transfection Kit 5 transfections from BD Biosciences Pharmingen
Sf9 Insect Cells from BD Biosciences Pharmingen
UltraClean Plant DNA Isolation Kit from Mo Bio Laboratories, Inc.
Propidium iodide from Research Organics, Inc.
Biology Products: